ReCode is set to secure up to $15m in funding from the Cystic Fibrosis Foundation to enhance its gene correction research ...
Intellia Therapeutics (NTLA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 16. Analyst ...
Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold ...
As BridgeBio approaches its FDA target date for approval of TTR stabilizer acoramidis to treat the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM), the company has presented more ...
Ken Hawkins, a retired teacher from Grants Pass, is first Oregon participant in phase 3 clinical trial Ken Hawkins, a 77-year ...
Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.
Intellia Therapeutics ( (NTLA) ) just unveiled an announcement.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top ...
Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...
In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback